NCT01573572已完成4 期
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 131
- 试验地点
- 4
- 主要终点
- Change From Baseline in Mean Endothelial Cell Density
研究概览
简要总结
This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval clinical study to support that there are no adverse effects on the corneal endothelium following intravitreal injections of Macugen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects of either gender aged > or = to 50 years diagnosed with subfoveal neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, or Retinal Vein Occlusion.
- •Best corrected visual acuity in the study eye between 85 and 20 ETDRS letters or between 20/20 and 20/400 using a Snellen chart.
- •Women must be using two forms of effective contraception, be post-menopausal for at least 12 months prior to study entry, or surgically sterile; if of child-bearing potential, a urine pregnancy test must be performed within 7 days prior to the first injection with a negative result. If the test is positive, a serum test must be done to confirm. The two forms of effective contraception must be implemented during the study and for at least 60 days following the last dose of test medication.
- •Provide written informed consent.
- •Ability to return for all study visits.
排除标准
- •Subjects will not be eligible for the study if subjects cannot attend all study-required visits, or if any of the following criteria are present
- •Unilateral ocular blunt trauma within one year of enrollment and no greater than 5% difference in central endothelial cell density between the 2 eyes.
- •intraocular surgery (cataract surgery and surgery for glaucoma without tube shunt or mini-shunt) within one year of enrollment.
- •Anterior segment laser surgery (laser trabeculoplasty) performed within one year of enrollment.
- •Glaucoma tube-shunt surgery
- •Previous history of corneal transplant in the study or non-study eye
- •Presence of vitreous macular traction
- •Previous therapeutic radiation in the region of the study eye
- •Any treatment with an investigational agent in the past 30 days for any condition
- •Known serious allergies to the components of pegaptanib sodium formulation
- •Any of the following underlying diseases including:
- •History or evidence of severe cardiac disease(e.g. NYHA Functional Class III or IV - see Appendix 2), clinical or medical history of unstable angina, acute coronary syndrome, myocardial infarction or revascularization within 6 months, ventricular tachyarrhythmias requiring ongoing treatment
- •History or evidence of clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation
- •History or evidence of clinically significant impaired renal or hepatic function
- •Stroke (within 12 months of study entry)
- •Any major surgical procedure within one month of study entry
- •Significant media opacities, including cataract, which might interfere with visual acuity, assessment of toxicity. Subjects should not be entered if there is likelihood that they will require cataract or glaucoma surgery in either eye during the study treatment and follow-up period.
研究组 & 干预措施
Intravitreal Injections of Macugen
Experimental
干预措施: pegaptanib sodium injection (Drug)
结局指标
主要结局
Change From Baseline in Mean Endothelial Cell Density
时间窗: Baseline, Week 54
The effect on the corneal endothelium will be assessed by specular microscopy, by assessing mean cell density change from baseline. This is to evaluate that there are no adverse effects on the corneal endothelium following intravitreal injections of Macugen.
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
4 期
An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. AnthracisInfection, BacterialAnthraxNCT03088111Elusys Therapeutics100
进行中（未招募）
不适用
The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)ObesityNCT05368259Allurion Technologies1,000
已完成
3 期
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)Short Bowel SyndromeNCT02340819Shire11
已完成
4 期
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry DiseaseFabry DiseaseNCT00140621Genzyme, a Sanofi Company6
进行中（未招募）
1 期
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCEGFR-mutant Non-small Cell Lung CancerNCT03333343Novartis Pharmaceuticals105